FDA to Review a Preventative RSV Treatment Developed for Infant Population
The FDA accepted the biologics license application (BLA) for nirsevimab (Beyfortus; AstraZeneca), which is an antibody indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants entering or during …
See Original Article
Leave a Reply